Make a ppt of pachychoroid spectrum disorder and CSCR from very basics to advanced level including recent advances and clinical trials from standard textbook of ophthalmology including it from Ryan's retina
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Finding Sources
Reading File
Searching PubMed
pachychoroid spectrum disorder treatment
Searching PubMed
central serous chorioretinopathy treatment clinical trial
Searching the Web
Ryan's Retina pachychoroid spectrum CSCR central serous chorioretinopathy 2024 2025
Reading File
Reading File
Reading Web Page
pachychoroid spectrum CSCR pathogenesis treatment recent advances
Reading File
Finding Sources
Searching PubMed
pachychoroid neovasculopathy polypoidal choroidal vasculopathy classification
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Reading File
Running Command
Writing File
Running Command
Running Command
Your presentation is ready:
Pachychoroid CSCR Spectrum
Presentation · PPTX
What's Inside (31 Slides)
The deck is structured with a deep navy + cyan-blue color theme for a professional ophthalmology look. Here's the full outline:
| # | Section | Content |
|---|---|---|
| 1 | Title Slide | Full title with source references |
| 2 | Agenda | 14-point visual outline with numbered badges |
| 3 | Section Banner | Pachychoroid Basics |
| 4 | Definition | Etymology, Spaide's concept, normal SFCT values |
| 5 | Choroidal Anatomy | All 5 layers, EDI-OCT, intervortex anastomoses |
| 6 | Pathophysiology | 8-step mechanism: pachyvessels → RPE failure → SRF; molecular players (CFH, MR, VEGF) |
| 7 | Spectrum Table | Classification table: PPE → CSCR → PPS → PNV → PCV |
| 8 | Section Banner | CSCR Deep Dive |
| 9 | History & Epidemiology | von Graefe (1866) to Spaide (2018); "PSR" renaming |
| 10 | Risk Factors | Two-column: strong vs associated factors |
| 11 | Pathophysiology Detail | 6-step mechanism + glucocorticoid pathway + Ryan's Retina concept |
| 12 | Acute vs Chronic | Two-column clinical comparison |
| 13 | Section Banner | Multimodal Imaging |
| 14 | OCT/EDI-OCT | All OCT signs including double-layer sign, pachyvessels |
| 15 | FA & ICGA | Inkblot vs smokestack; ICGA as gold standard for hyperpermeability |
| 16 | FAF & OCTA | Gravitational tract; medusa CNV pattern; flow deficits |
| 17 | Differential Diagnosis | 7-condition table (AMD, PCV, disc pit, VKH, metastasis, etc.) |
| 18 | Section Banner | Management |
| 19 | Management Framework | 7-step algorithm from observation to anti-VEGF |
| 20 | PDT in Detail | Half-dose vs half-fluence; Cochrane NMA 2025 evidence |
| 21 | Other Treatments | STML, spironolactone, conventional laser, anti-VEGF, novel agents |
| 22 | Section Banner | PCV |
| 23 | PCV | Clinical features + ICGA gold standard + EVEREST II principle + faricimab 2025 |
| 24 | PNV & PPE | Continuum concept; double-layer sign; no treatment needed for PPE |
| 25 | Section Banner | Recent Advances |
| 26 | Recent Advances | PSR renaming, CVI, AI, ICGA fingerprints, faricimab, RELITE, controversies review 2026 |
| 27 | Clinical Trials Table | 7 landmark trials 2023–2026 (Cochrane NMA, Brelen RCT, Gao RCT, Kim et al. 2025, etc.) |
| 28 | Prognosis & Complications | CNV risk, bullous CSCR, prognostic factors, microperimetry |
| 29 | Ryan's Retina Concepts | 7 key principles from Ryan's Retina on pachychoroid |
| 30 | Summary & Takeaways | 10 numbered key points |
| 31 | References | 13 citations (Kanski, Ryan's, PMIDs, journals) |
This is a shared conversation. Sign in to Orris to start your own chat.